Clinical Study
Is Anticoagulation Discontinuation Achievable with Citrate Dialysate during HDF Sessions?
Table 1
Baseline demographic and clinical characteristics.
| Numbers of patients | | 28 | | Age (years) | | 71.3 (±15.4) | | Men/women | | 20 (71.4%)/8 (28.6%) | | Time on dialysis (years) | | 3.2 (±3.2) | | Causal nephropathy | | 12 vascular and/or diabetic nephropathy | | 5 interstitial or obstructive nephropathy | | 4 glomerular disease | | 3 undetermined | | 2 anticalcineurin nephropathy | | 2 polycystic kidney disease | | Nadroparine per session (UI/kg) | | 52.4 UI/kg (±18.6) | | Erythropoietin per session (UI/kg) | | 137 UI/kg (±144) | | Vitamin K antagonists (VKA)/antiplatelet | | 6 no treatment | | 11 aspirin alone | | 2 clopidogrel alone | | 3 aspirin and clopidogrel | | 4 VKA | | 2 VKA and antiplatelet | | CRP (mg/L) | | 6.9 (±6.5) | | Hemoglobin (g/dL) | | 11.6 (±1.0) | |
|
|